Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
10:31am, Monday, 27'th Apr 2026
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a
AEGON ASSET MANAGEMENT UK Plc Has $20.60 Million Position in Veracyte, Inc. $VCYT
03:10am, Sunday, 26'th Apr 2026
AEGON ASSET MANAGEMENT UK Plc lifted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Se
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
04:05pm, Tuesday, 14'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 aft
Comparing Advanced Biomedical Technologies (OTCMKTS:ABMT) and Veracyte (NASDAQ:VCYT)
02:21am, Monday, 06'th Apr 2026
Veracyte (NASDAQ: VCYT - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two
Is Veracyte Stock the Right Pick for Your Portfolio Now?
09:27am, Tuesday, 31'st Mar 2026
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?
12:36pm, Friday, 27'th Mar 2026
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte Names Kevin Haas as Chief Development and Technology Officer
04:15pm, Monday, 16'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT
04:23am, Monday, 16'th Mar 2026
Bamco Inc. NY lowered its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
Artisan Partners Limited Partnership Acquires 1,048,692 Shares of Veracyte, Inc. $VCYT
03:26am, Friday, 27'th Feb 2026
Artisan Partners Limited Partnership raised its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.6% during the third quarter, according to its most recent filing with the Securities and Excha
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises
12:25pm, Thursday, 26'th Feb 2026
VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.
Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells
07:30am, Thursday, 26'th Feb 2026
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
10:17pm, Wednesday, 25'th Feb 2026
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates
09:06pm, Wednesday, 25'th Feb 2026
Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Wednesday, 25'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
09:00am, Tuesday, 24'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.
